385 related articles for article (PubMed ID: 12059113)
1. The development and use of vaccine adjuvants.
Edelman R
Mol Biotechnol; 2002 Jun; 21(2):129-48. PubMed ID: 12059113
[TBL] [Abstract][Full Text] [Related]
2. European union regulatory developments for new vaccine adjuvants and delivery systems.
Sesardic D; Dobbelaer R
Vaccine; 2004 Jun; 22(19):2452-6. PubMed ID: 15193409
[TBL] [Abstract][Full Text] [Related]
3. Survey of human-use adjuvants.
Kenney RT; Edelman R
Expert Rev Vaccines; 2003 Apr; 2(2):167-88. PubMed ID: 12899569
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant Systems for vaccines: 13 years of post-licensure experience in diverse populations have progressed the way adjuvanted vaccine safety is investigated and understood.
Laupèze B; Hervé C; Di Pasquale A; Tavares Da Silva F
Vaccine; 2019 Sep; 37(38):5670-5680. PubMed ID: 31420171
[TBL] [Abstract][Full Text] [Related]
5. Flagellin as a vaccine adjuvant.
Cui B; Liu X; Fang Y; Zhou P; Zhang Y; Wang Y
Expert Rev Vaccines; 2018 Apr; 17(4):335-349. PubMed ID: 29580106
[TBL] [Abstract][Full Text] [Related]
6. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW
Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624
[TBL] [Abstract][Full Text] [Related]
7. Design and selection of vaccine adjuvants: animal models and human trials.
Alving CR
Vaccine; 2002 May; 20 Suppl 3():S56-64. PubMed ID: 12184368
[TBL] [Abstract][Full Text] [Related]
8. Vaccine adjuvants: Why and how.
Christensen D
Hum Vaccin Immunother; 2016 Oct; 12(10):2709-2711. PubMed ID: 27551808
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulators as adjuvants for vaccines and antimicrobial therapy.
Nicholls EF; Madera L; Hancock RE
Ann N Y Acad Sci; 2010 Dec; 1213():46-61. PubMed ID: 20946578
[TBL] [Abstract][Full Text] [Related]
10. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile.
Podda A; Del Giudice G
Expert Rev Vaccines; 2003 Apr; 2(2):197-203. PubMed ID: 12899571
[TBL] [Abstract][Full Text] [Related]
11. Toward precision adjuvants: optimizing science and safety.
Nanishi E; Dowling DJ; Levy O
Curr Opin Pediatr; 2020 Feb; 32(1):125-138. PubMed ID: 31904601
[TBL] [Abstract][Full Text] [Related]
12. Laser vaccine adjuvants. History, progress, and potential.
Kashiwagi S; Brauns T; Gelfand J; Poznansky MC
Hum Vaccin Immunother; 2014; 10(7):1892-907. PubMed ID: 25424797
[TBL] [Abstract][Full Text] [Related]
13. The impact of size on particulate vaccine adjuvants.
Shah RR; O'Hagan DT; Amiji MM; Brito LA
Nanomedicine (Lond); 2014 Dec; 9(17):2671-81. PubMed ID: 25529570
[TBL] [Abstract][Full Text] [Related]
14. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.
Leroux-Roels I; Borkowski A; Vanwolleghem T; Dramé M; Clement F; Hons E; Devaster JM; Leroux-Roels G
Lancet; 2007 Aug; 370(9587):580-9. PubMed ID: 17707753
[TBL] [Abstract][Full Text] [Related]
15. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of vaccine potency through improved delivery.
Ulmer JB
Expert Opin Biol Ther; 2004 Jul; 4(7):1045-51. PubMed ID: 15268672
[TBL] [Abstract][Full Text] [Related]
17. Novel vaccines and adjuvant systems: the utility of animal models for predicting immunogenicity in humans.
Davis HL
Hum Vaccin; 2008; 4(3):246-50. PubMed ID: 18382138
[TBL] [Abstract][Full Text] [Related]
18. The path to a successful vaccine adjuvant--'the long and winding road'.
O'Hagan DT; De Gregorio E
Drug Discov Today; 2009 Jun; 14(11-12):541-51. PubMed ID: 19508916
[TBL] [Abstract][Full Text] [Related]
19. An overview of adjuvants utilized in prophylactic vaccine formulation as immunomodulators.
Chauhan N; Tiwari S; Iype T; Jain U
Expert Rev Vaccines; 2017 May; 16(5):491-502. PubMed ID: 28285554
[TBL] [Abstract][Full Text] [Related]
20. An overview on the role of silica-based materials in vaccine development.
Navarro-Tovar G; Palestino G; Rosales-Mendoza S
Expert Rev Vaccines; 2016 Nov; 15(11):1449-1462. PubMed ID: 27160927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
